UNSPSC 51333502: Domperidone

This classification denotes an antipsychotic agent with the molecular formula C22H24ClN5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5587267Z69, chemically known as 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1h-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-2h-benzimidazol-2-one but generally known as domperidone, which bears US NIH Compound Identifier 3151. European Medicines Agency schedules Domperidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06361MIG.

UNSPSC 51333502 Domperidone is a Commodity code nominally describing a single pharmaceutical product, but recent state and local procurement activity under this code shows little alignment with domperidone specifically. Instead, issuing bodies are soliciting broader pharmaceutical procurement — generic multi-source drugs, over-the-counter products, naloxone, and direct-to-manufacturer prescription programs. The work involves establishing supply contracts for high-volume pharmaceutical distribution to public health systems, community health facilities, and state employee benefit programs, with vendors typically required to work through authorized wholesalers or direct manufacturing relationships, maintain FDA compliance and cGMP certification, submit detailed product information including National Drug Codes and pricing structures, and deliver quarterly or ongoing supplies to specified locations.

Recent activity spans state health and human services agencies, county health departments, and cooperative purchasing alliances. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026, requiring submission through the ePro system and participation from at least two of three authorized wholesalers. Seminole County, Florida posted an IFB in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries and a July 26, 2023 response deadline. The Texas Health and Human Services Commission issued an RFI in April 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs serving state employee health plans. Activity concentrates in Florida, Minnesota (and participating states including Oregon), and Texas, with issuing bodies including county health departments, state procurement offices, and regional cooperative purchasing organizations. The code sees active use in pharmaceutical supply contracting but shows limited recent opportunities tagged specifically under domperidone as a discrete product line.